BACKGROUND: Breast cancer patients regularly undergo adjuvant chemotherapies following surgery. However, these treatments are largely associated with chemotherapeutic toxicities ranging from nausea to severe myelosuppression. In this investigation, we examined the effects of four SNPs in NR1I2, CYP3A4 and CYP3A5 genes on chemotherapy-induced severe neutropenia in 311 female Chinese breast cancer patients undergoing a standard adjuvant chemotherapy regimen. METHODS: Patients were monitored for adverse reactions throughout the treatment, then divided into "none or mild" (80 %) or "severe" (20 %) toxicity groups according to whether they suffered grade 4 neutropenia defined as having an absolute neutrophil counts (ANC) of less than 0.5 × 10(9)/L anytime during the treatment. DNA was extracted from patients' peripheral blood samples, then genotyped using allele-specific Tm-shift PCR and melting analysis. RESULTS: Logistic regression revealed that rs776746 or CYP3A5*3 strongly associated with grade 4 neutropenia (OR = 2.56, P = 0.023) after adjustment for covariates, one of which more significant factor was baseline ANC (OR = 0.68, P = 0.020). Although univariate analysis in all patients did not reveal any association at first, further analysis indicated that rs776746 is significantly associated with severe neutropenia in subgroup of breast cancer patients with normal baseline ANC (≥2.0 × 10(9)/L). These carriers of A-allele have 3.14-fold increased risk of developing severe neutropenia (P = 0.004). CONCLUSION: Our results suggested that polymorphisms in CYP3A5 might be useful pharmacogenetic markers for the prediction of severe neutropenia during chemotherapy, however, only after screening patients by their baseline ANC in the presence of gene-environmental interaction. We demonstrate an approach of pharmacogenetic analysis, in which the genetic data should be analyzed in the perspective of other clinical parameters.
BACKGROUND:Breast cancerpatients regularly undergo adjuvant chemotherapies following surgery. However, these treatments are largely associated with chemotherapeutic toxicities ranging from nausea to severe myelosuppression. In this investigation, we examined the effects of four SNPs in NR1I2, CYP3A4 and CYP3A5 genes on chemotherapy-induced severe neutropenia in 311 female Chinese breast cancerpatients undergoing a standard adjuvant chemotherapy regimen. METHODS:Patients were monitored for adverse reactions throughout the treatment, then divided into "none or mild" (80 %) or "severe" (20 %) toxicity groups according to whether they suffered grade 4 neutropenia defined as having an absolute neutrophil counts (ANC) of less than 0.5 × 10(9)/L anytime during the treatment. DNA was extracted from patients' peripheral blood samples, then genotyped using allele-specific Tm-shift PCR and melting analysis. RESULTS: Logistic regression revealed that rs776746 or CYP3A5*3 strongly associated with grade 4 neutropenia (OR = 2.56, P = 0.023) after adjustment for covariates, one of which more significant factor was baseline ANC (OR = 0.68, P = 0.020). Although univariate analysis in all patients did not reveal any association at first, further analysis indicated that rs776746 is significantly associated with severe neutropenia in subgroup of breast cancerpatients with normal baseline ANC (≥2.0 × 10(9)/L). These carriers of A-allele have 3.14-fold increased risk of developing severe neutropenia (P = 0.004). CONCLUSION: Our results suggested that polymorphisms in CYP3A5 might be useful pharmacogenetic markers for the prediction of severe neutropenia during chemotherapy, however, only after screening patients by their baseline ANC in the presence of gene-environmental interaction. We demonstrate an approach of pharmacogenetic analysis, in which the genetic data should be analyzed in the perspective of other clinical parameters.
Authors: S Y Hor; S C Lee; C I Wong; Y W Lim; R C Lim; L Z Wang; L Fan; J Y Guo; H S Lee; B C Goh; T Tan Journal: Pharmacogenomics J Date: 2007-09-18 Impact factor: 3.550
Authors: Meredith M Regan; Brian Leyland-Jones; Mark Bouzyk; Olivia Pagani; Weining Tang; Roswitha Kammler; Patrizia Dell'orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Patrick Neven; Marc Debled; Rudolf Maibach; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch; James M Rae; Giuseppe Viale Journal: J Natl Cancer Inst Date: 2012-03-06 Impact factor: 13.506
Authors: Hyo Sook Han; Isildinha M Reis; Wei Zhao; Katsumasa Kuroi; Masakazu Toi; Eiji Suzuki; Rachel Syme; Louis Chow; Adrian Y S Yip; Stefan Glück Journal: Eur J Cancer Date: 2011-07-07 Impact factor: 9.162
Authors: N Fleeman; C Martin Saborido; K Payne; A Boland; R Dickson; Y Dundar; A Fernández Santander; S Howell; W Newman; J Oyee; T Walley Journal: Health Technol Assess Date: 2011-09 Impact factor: 4.014
Authors: Song Yao; William E Barlow; Kathy S Albain; Ji-Yeob Choi; Hua Zhao; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Gabriel N Hortobagyi; Daniel F Hayes; Christine B Ambrosone Journal: Breast Cancer Res Treat Date: 2010-03-23 Impact factor: 4.872
Authors: Helen K Chew; James H Doroshow; Paul Frankel; Kim A Margolin; George Somlo; Heinz-Josef Lenz; Michael Gordon; Wu Zhang; Dongyun Yang; Christy Russell; Darcy Spicer; Tim Synold; Robert Bayer; Alexander Hantel; Patrick J Stiff; Merry L Tetef; David R Gandara; Kathy S Albain Journal: J Clin Oncol Date: 2009-03-23 Impact factor: 44.544
Authors: Lillian Sung; Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Wang; Soheil Meshinchi; Alan S Gamis Journal: Int J Cancer Date: 2016-07-04 Impact factor: 7.396
Authors: Behzad Bidadi; Duan Liu; Krishna R Kalari; Matthias Rubner; Alexander Hein; Matthias W Beckmann; Brigitte Rack; Wolfgang Janni; Peter A Fasching; Richard M Weinshilboum; Liewei Wang Journal: Front Pharmacol Date: 2018-03-13 Impact factor: 5.810
Authors: Alena M Pfeil; Christof Vulsteke; Robert Paridaens; Anne-Sophie Dieudonné; Ruth Pettengell; Sigrid Hatse; Patrick Neven; Diether Lambrechts; Thomas D Szucs; Matthias Schwenkglenks; Hans Wildiers Journal: BMC Cancer Date: 2014-03-19 Impact factor: 4.430
Authors: Peter A Fasching; Lothar Häberle; Brigitte Rack; Liang Li; Alexander Hein; Arif B Ekici; Andre Reis; Michael P Lux; Julie M Cunningham; Matthias Ruebner; Gergory Jenkins; Brooke Fridley; Andreas Schneeweiss; Hans Tesch; Werner Lichtenegger; Tanja Fehm; Georg Heinrich; Mahdi Rezai; Matthias W Beckmann; Wolfgang Janni; Richard M Weinshilboum; Liewei Wang Journal: Oncotarget Date: 2017-05-09
Authors: Annelot G J van Rossum; Marleen Kok; Danielle McCool; Mark Opdam; Nienke C Miltenburg; Ingrid A M Mandjes; Elise van Leeuwen-Stok; Alex L T Imholz; Johanneke E A Portielje; Monique M E M Bos; Aart van Bochove; Erik van Werkhoven; Marjanka K Schmidt; Hendrika M Oosterkamp; Sabine C Linn Journal: Oncotarget Date: 2017-11-27